Baxter International Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Baxter International Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Baxter International Inc. - Product Pipeline Review - 2014', provides an overview of the Baxter International Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Baxter International Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Baxter International Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Baxter International Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Baxter International Inc.'s pipeline products

Reasons to buy

- Evaluate Baxter International Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Baxter International Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Baxter International Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Baxter International Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Baxter International Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Baxter International Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Baxter International Inc. Snapshot 6
Baxter International Inc. Overview 6
Key Information 6
Key Facts 6
Baxter International Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Baxter International Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Baxter International Inc. - Pipeline Products Glance 15
Baxter International Inc. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Baxter International Inc. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Baxter International Inc. - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Baxter International Inc. - Drug Profiles 21
(human normal immunoglobulin + recombinant human hyaluronidase) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
A/H5N1 prepandemic influenza vaccine (whole virion, vero-cell-derived, inactivated) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
coagulation factor IX (recombinant) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
OBI-1 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Adult Autologous CD34plus Stem Cells 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BAX-817 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BAX-855 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
meningococcal conjugate vaccine, adsorbed 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Ross River Virus Vaccine 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
vonicog alfa 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Multivalent Recombinant OspA Lyme Borreliosis Vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TAK-850 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vaccine for Influenza H9N2 Infections 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BAX-69 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BAX-930 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Plasma Derived Butyrylcholinesterase 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BAX-826 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BaxB-01 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BaxG-03 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BaxM-159 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Synthetic Peptide to Inhibit Tissue Factor Pathway for Hemophilia 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Baxter International Inc. - Pipeline Analysis 50
Baxter International Inc. - Pipeline Products by Target 50
Baxter International Inc. - Pipeline Products by Route of Administration 52
Baxter International Inc. - Pipeline Products by Molecule Type 53
Baxter International Inc. - Pipeline Products by Mechanism of Action 54
Baxter International Inc. - Recent Pipeline Updates 55
Baxter International Inc. - Dormant Projects 64
Baxter International Inc. - Discontinued Pipeline Products 65
Discontinued Pipeline Product Profiles 65
BAX-499 65
Baxter International Inc. - Company Statement 66
Baxter International Inc. - Locations And Subsidiaries 68
Head Office 68
Other Locations & Subsidiaries 68
Baxter International Inc. - Key Manufacturing Facilities 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Baxter International Inc., Key Information 6
Baxter International Inc., Key Facts 6
Baxter International Inc. - Pipeline by Indication, 2014 9
Baxter International Inc. - Pipeline by Stage of Development, 2014 10
Baxter International Inc. - Monotherapy Products in Pipeline, 2014 11
Baxter International Inc. - Combination Treatment Modalities in Pipeline, 2014 12
Baxter International Inc. - Partnered Products in Pipeline, 2014 13
Baxter International Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14
Baxter International Inc. - Pre-Registration, 2014 15
Baxter International Inc. - Phase III, 2014 16
Baxter International Inc. - Phase II, 2014 17
Baxter International Inc. - Phase I, 2014 18
Baxter International Inc. - Preclinical, 2014 19
Baxter International Inc. - Discovery, 2014 20
Baxter International Inc. - Pipeline by Target, 2014 51
Baxter International Inc. - Pipeline by Route of Administration, 2014 52
Baxter International Inc. - Pipeline by Molecule Type, 2014 53
Baxter International Inc. - Pipeline Products by Mechanism of Action, 2014 54
Baxter International Inc. - Recent Pipeline Updates, 2014 55
Baxter International Inc. - Dormant Developmental Projects,2014 64
Baxter International Inc. - Discontinued Pipeline Products, 2014 65
Baxter International Inc., Other Locations 68
Baxter International Inc., Subsidiaries 69
Baxter International Inc., Key Manufacturing Facilities 73